No Data
Peking Green Bamboo Biotechnology Co., Ltd. 2024 Annual Performance Communication Meeting.
Hong Kong, April 22, 2025 / PR Newswire / -- Peking Green Bamboo Biotechnology Co., Ltd. ("Green Bamboo Biotechnology" or "the Company") recently held its 2024 annual performance exchange meeting, attracting many investors and Analysts to actively participate and ask questions, reflecting investors' high expectations for the Company's future development. 2024 Important Milestones In the past year, Green Bamboo Biotechnology has achieved several important milestones, particularly making significant progress in the commercialization process of its core product, the herpes vaccine LZ901. The Phase III clinical trial of LZ901 was completed in January 2024.
LUZHU BIOTECH-B: Annual Report 2024
LUZHU BIOTECH-B (02480) nominates Kong Jian as a candidate for executive director of the fifth Board of Directors.
LUZHU BIOTECH-B (02480) announced that, after considering the recommendation of the Board of Directors' Nomination Committee, the Board of Directors decided to...
Technological breakthroughs and innovation leadership, how LUZHU BIOTECH-B (2480.HK) reshapes the vaccine industry landscape.
In the context of the Global vaccine Industry accelerating technological iteration and market expansion, Chinese Biomedical companies are reshaping the industry landscape through innovative breakthroughs. With the validation of mRNA technology, the acceleration of multi-valent vaccine research and development, and the continuous release of significant products such as the shingles vaccine, the vaccine industry has entered a new stage driven by "independent innovation + globalization." Recently, Luzhu Biomedical released its 2024 annual performance report, showcasing breakthrough progress in its core product LZ901 shingles vaccine, as well as the layout of innovative vaccine pipelines such as HSV-1/HSV-2, demonstrating the technical prowess of Chinese innovative vaccine companies.
[Brokerage Focus] Jianyin International maintains an outperform rating on Greentown Biotech (02480), stating that its full-year performance for 2024 will exceed expectations.
Jinwu Financial News | Jianyin International's Research Reports indicate that for Greentube Biotech (02480), the performance in the second half of 2024 and for the entire year of 2024 exceeds expectations, with a net loss improving compared to the previous year. Excluding one-off items, the bank's adjusted net loss estimates for the second half of 2024 and for the entire year of 2024 are 0.167 billion yuan and 58 million yuan, respectively, better than their previous estimates of 0.282 billion yuan and 0.173 billion yuan loss, and compared to the losses of 0.223 billion yuan and 0.17 billion yuan in the second half of 2023 and for the entire year of 2023, the situation is not as severe.
Luzhu Biotechnology's Attributable Loss Narrows in 2024